

Recent increase in adverse TMP-SMX reactions in children

December 3 2012



There has been a significant increase in adverse drug reactions associated with use of trimethoprim-sulfamethoxazole for treatment of skin and soft tissue infection in children, according to research published online Dec. 3 in *Pediatrics*.

(HealthDay)—There has been a significant increase in adverse drug reactions (ADRs) associated with use of trimethoprim-sulfamethoxazole (TMP-SMX) for treatment of skin and soft tissue infection (SSTI) in children, according to research published online Dec. 3 in *Pediatrics*.

Jennifer L. Goldman, M.D., from the University of Missouri in Kansas City, and colleagues conducted a retrospective chart review to characterize TMP-SMX ADRs in children, from 2000 to 2009. The Pediatric Health Information System database was used to estimate the frequency of hospitalizations for TMP-SMX ADRs at 25 tertiary pediatric hospitals.

The researchers found that, at the study institution, there were five cases



of TMP-SMX ADRs from 2000 to 2004, compared with 104 cases from 2005 to 2009. Of the cases, 58 percent had been treated for SSTI. Nationally, there was a similar trend, with the incidence of TMP-SMX ADRs more than doubling (P

"TMP-SMX ADRs have occurred more frequently coincident with increased prescribing for SSTI," the authors write. "Increased usage alone may explain the increasing trend of TMP-SMX ADRs in children; however, drug-disease interaction may play a role and requires further investigation."

More information: Abstract

Full Text (subscription or payment may be required)

Copyright © 2012 HealthDay. All rights reserved.

Citation: Recent increase in adverse TMP-SMX reactions in children (2012, December 3) retrieved 6 May 2024 from

https://medicalxpress.com/news/2012-12-adverse-tmp-smx-reactions-children.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.